Synopsis: The competition for complex respiratory generics in the U.S. is intensifying as drug companies seek to move beyond traditional medicines and target high-value speciality segments. In line with this strategy, Cipla has achieved a major regulatory milestone, which not only expands its presence in the world’s largest pharmaceutical market but also enhances its manufacturing capabilities in a technology-intensive product category.
Respiratory therapy is one of the most competitive and complex areas of the pharmaceutical industry. The inhaler business is a high-barrier business that requires sophisticated formulation, manufacturing and regulatory approvals. With healthcare systems moving towards cost-effective generic alternatives, there are major market opportunities for developers of complex inhalation products. In this context, Cipla achieved yet another milestone in the US respiratory business.
Shares of Cipla Limited were trading at Rs 1,434.7, up by 1.8%. The company’s current market capitalisation is Rs 1,16,132 crore, and it is trading at a P/E ratio of 32.5, slightly lower than the industry peer median of 34.53.
Cipla Receives USFDA Approval for Generic Advair Diskus
Cipla Limited announced that it has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus (fluticasone propionate and salmeterol inhalation powder) across all three dosage strengths—100/50 mcg, 250/50 mcg and 500/50 mcg.
The product is a therapeutically equivalent version of the branded Advair Diskus, which is widely prescribed for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
An ANDA (Abbreviated New Drug Application) allows pharmaceutical companies to market generic versions of approved medicines after demonstrating therapeutic equivalence without repeating the extensive clinical trials required for the original product. The company expects to launch the product commercially during Q2 FY27 in the United States.
Targets a $908 Million U.S. Market Opportunity
According to IQVIA, the U.S. market for fluticasone propionate and salmeterol inhalation powder is estimated at $908 million, making it one of the larger opportunities within the respiratory generics segment. By entering this market, Cipla aims to further strengthen its presence in complex inhalation therapies, an area where regulatory approvals remain difficult due to the technological complexity involved in developing inhaler-based medicines.
Unlike conventional oral medicines, dry powder inhalers require precise drug formulation, specialised device engineering and consistent dose delivery, making successful approvals a significant competitive advantage.
First Dry Powder Inhaler Approved from U.S. Manufacturing Network
According to Cipla, this is the first Dry Powder Inhaler (DPI) approved from its U.S.-based manufacturing network, highlighting the company’s growing capabilities in developing and manufacturing complex respiratory products within the United States. The product has been developed through Cipla’s vertically integrated inhalation platform, which combines product development, manufacturing and supply chain capabilities under a single integrated system.
Strengthening local manufacturing also enhances supply chain resilience while supporting the company’s long-term strategy of expanding its footprint in the U.S. generic pharmaceuticals market.
Management Highlights Long-Term Respiratory Strategy
Commenting on the approval, Achin Gupta, Managing Director and Global CEO of Cipla, said the company has long considered respiratory care a strategic focus area. He noted that the approval reinforces Cipla’s commitment to expanding patient access to complex therapies while showcasing its ability to develop and scale sophisticated inhalation products.
Marc Falkin, Chief Executive Officer of Cipla North America, added that the approval represents the first dry powder inhaler manufactured from the company’s New York facility and reflects targeted investments aimed at building differentiated inhalation manufacturing capabilities in the U.S., enabling the company to provide a reliable supply in a highly competitive therapeutic category.
Strategic Insight and Industry Analysis
The latest USFDA approval further strengthens Cipla’s position in one of the pharmaceutical industry’s highest-entry-barrier segments. Unlike traditional generic medicines, respiratory inhalation products require specialised formulation expertise, sophisticated manufacturing infrastructure and stringent regulatory compliance, limiting competition and creating opportunities for companies with proven capabilities.
Beyond adding another product to its portfolio, the approval also validates Cipla’s investments in U.S.-based manufacturing and complex respiratory technologies. Investors are likely to monitor the commercial launch in Q2 FY27, market share gains within the $908 million opportunity and the contribution of high-value respiratory products to the company’s North American business over the coming quarters.
Cipla Limited is a global pharmaceutical company focused on complex generics and specialty medicines across respiratory, anti-retroviral, cardiology, urology, anti-infective and central nervous system therapies. Established in 1935, the company operates 46 manufacturing facilities, markets over 1,500 products across 70+ countries, and is among the leading pharmaceutical companies in the generics market in India, South Africa, and the U.S.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
